Welcome to our dedicated page for Theravance Bioph news (Ticker: TBPH), a resource for investors and traders seeking the latest updates and insights on Theravance Bioph stock.
Theravance Biopharma, Inc. reports biopharmaceutical developments centered on YUPELRI® (revefenacin) inhalation solution, an FDA-approved maintenance treatment for chronic obstructive pulmonary disease. Company updates commonly address YUPELRI collaboration revenue, U.S. net sales recognized by Viatris, hospital-channel demand, brand profitability, and intellectual-property matters related to generic challenges.
Theravance news also covers portfolio changes following the Phase 3 CYPRESS study of ampreloxetine in symptomatic neurogenic orthostatic hypotension due to multiple system atrophy, including the decision to wind down that program. Recurring corporate updates include cost-reduction actions, operating expense trends, TRELEGY milestone economics reported by GSK, cash position, and governance or capital-allocation reviews.
Theravance Biopharma (NASDAQ: TBPH) will present two rapid-fire analyses of YUPELRI (revefenacin) at the 2025 CHEST Annual Meeting in Chicago, Oct 19–22, 2025.
A retrospective claims study reported that patients adherent to YUPELRI after COPD hospital discharge had significantly fewer and less severe exacerbations and significantly lower healthcare costs versus non-adherent patients. Post-hoc analyses of a 52-week Phase 3 safety study found lower incidence of moderate-to-severe exacerbations and overall less severe exacerbations versus tiotropium. Presentation details list presenters, titles, and Oct 21, 2025 times.
Theravance Biopharma (NASDAQ: TBPH) announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference in New York City. CEO Rick Winningham will engage in a Fireside Chat on September 9, 2025, at 1:30 PM EDT.
The company will offer in-person meeting opportunities for interested investors through H.C. Wainwright representatives. A live webcast will be available online, with a replay accessible on Theravance's website for 30 days following the event.
Theravance Biopharma (NASDAQ: TBPH) has completed enrollment in its pivotal Phase 3 CYPRESS study of ampreloxetine for treating symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA). The study targets an underserved population of approximately 40,000 U.S. patients.
The CYPRESS trial is a global, randomized-withdrawal study with a 12-week open-label portion followed by an 8-week randomized phase. The company expects topline results in Q1 2026 and plans to pursue an expedited NDA submission with potential priority FDA review. Ampreloxetine has received Orphan Drug Designation in the U.S., highlighting the significant unmet need in treating nOH due to MSA.
Theravance Biopharma (NASDAQ:TBPH) reported strong Q2 2025 financial results, highlighted by YUPELRI® net sales of $66.3 million, representing a 22% year-over-year increase. The company completed a significant transaction, selling its TRELEGY ELLIPTA royalty interest to GSK for $225 million.
Key financial metrics include total revenue of $26.2 million and a net income of $54.8 million. The company maintains a robust balance sheet with $338.8 million in cash and no debt. The pivotal Phase 3 CYPRESS study for ampreloxetine is expected to complete enrollment by late summer, with top-line data anticipated six months later.
TRELEGY's year-to-date performance puts it on track to trigger a $50 million milestone payment in 2025, with Q2 2025 global net sales reaching approximately $1.1 billion.
Theravance Biopharma (NASDAQ: TBPH) has scheduled its second quarter 2025 financial results announcement and business update for August 12, 2025, after market close. The company will host a conference call and webcast at 5:00 pm ET on the same day.
Interested participants can pre-register for the telephone conference, while those preferring to listen via the internet can access the webcast through the company's website. A replay will be available for 30 days through September 11, 2025.
Theravance Biopharma (NASDAQ: TBPH) announced its participation in the upcoming BTIG Virtual Biotechnology Conference. The company will engage in a fireside chat on Wednesday, July 30 at 12:00 pm ET (9:00 am PT/5:00 pm IST). Senior management will also be available for one-on-one meetings with investors during the conference.
Interested parties can access the webcast or schedule meetings through their BTIG representative or by emailing uscorporateaccess@btig.com.
Theravance Biopharma (NASDAQ:TBPH) announced that its partner Viatris has received approval from China's NMPA for YUPELRI® (revefenacin), the first once-daily nebulized LAMA for COPD maintenance treatment in China.
The approval triggers a $7.5 million milestone payment to TBPH, with potential for additional sales-based milestones up to $37.5 million and tiered royalties of 14% to 20% on net sales in China. Viatris will handle all commercialization aspects.
TBPH's financial position includes $131 million in cash, $225 million from TRELEGY royalties sale to GSK, 35% of U.S. YUPELRI profits, and up to $150 million in potential TRELEGY milestone payments.
Theravance Biopharma (NASDAQ: TBPH) has announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference in New York City. The company will engage in a Fireside Chat on Tuesday, May 20 at 10:30 AM EDT at NASDAQ. Additionally, TBPH will conduct in-person meetings with the investment community during the conference.
Investors can access the webcast through Theravance's website under the Investors section, Events and Presentations. The webcast recording will remain available for replay on the company's website for 30 days following the event.
Theravance Biopharma (NASDAQ: TBPH) presented analyses of its Phase 3 program for ampreloxetine, a treatment for symptomatic neurogenic orthostatic hypotension (nOH), at the International MSA Congress. The subgroup analysis from the REDWOOD 0170 study showed that Multiple System Atrophy (MSA) patients experienced meaningful improvement in nOH symptoms after 16 weeks of treatment, with symptoms remaining stable in the ampreloxetine group while worsening in the placebo group.
Key findings revealed improved functional activities in treated patients and demonstrated ampreloxetine's sustained effect on standing blood pressure. Additional analysis from Study 0169 highlighted that MSA patients had the highest nOH symptom burden despite existing treatments, emphasizing the need for better therapies. These results support the ongoing CYPRESS registrational study in nOH and MSA patients.